Statement Regarding Xifaxan Intellectual Property Litigation

LAVAL, Quebec, May 17, 2017 -- (Healthcare Sales & Marketing Network) -- Salix Pharmaceuticals, Inc. and parent Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") and Actavis Laboratories, Inc., at Actavis' request,... Biopharmaceuticals, Litigation Valeant Pharmaceuticals, Actavis Laboratories, Xifaxan, rifaximin
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news